Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 15,685

Document Document Title
WO/2013/189241A1
A pyrimidine diamine derivative as represented by formula (I), pharmaceutical salts thereof, pharmaceutical compositions containing the derivative, a preparation method therefor, and pharmaceutical uses thereof. The compound and the phar...  
WO/2013/187727A1
The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for...  
WO/2013/183747A1
Provided is a material which can convert a skeleton muscle into a slow-fiber-type one and can improve or recover muscle mass or endurance. An agent for converting a skeleton muscle into a slow-fiber-type one, which comprises ginger or a ...  
WO/2013/181084A1
The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-l,2-diols and C4-C8aliphatic-l,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered...  
WO/2013/180271A1
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically accept...  
WO/2013/177176A1
Provided herein are methods of inducing differentiation of a mammalian myoblast into a mammalian myocyte that include contacting a mammalian myoblast with an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase k...  
WO/2013/177458A1
Phosphatidic acid, lyso-phosphatidic acid, and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachectic patients, as well...  
WO/2013/175266A1
Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of ph...  
WO/2013/175386A1
Phosphatidic acid, lyso-phosphatidic acid, glycerol-3-phosphate and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachec...  
WO/2013/177428A1
The present disclosure provides methods for increasing muscle contractility in a myotubular myopathy subject following administration of fewer than 20 doses of a chimeric polypeptide that has a myotubularin protein and an internalizing m...  
WO/2013/172681A1
The present invention relates to a pharmaceutical composition containing Kaempferia parviflora Wall. Ex. Baker extracts for treating muscle diseases, and more specifically to a pharmaceutical composition containing, as an active ingredie...  
WO/2013/173506A3
A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such a...  
WO/2013/170970A1
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4...  
WO/2013/173506A2
A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such a...  
WO/2013/170385A1
It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate c...  
WO/2013/166557A1
The invention provides a method for treating cachexia, weakness, fatigue, and/or fever in a subject, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist. The method is particularl...  
WO/2013/170189A1
Methods of improving muscle energetics, muscle blood flow, and muscle health in humans, and specifically in adults and older adults, use nutritional compositions including a combination of beta-hydroxy-beta-methylbutyrate and beta-alanin...  
WO/2013/155330A1
Compositions and methods for identifying new treatments for Facioscapulohumeral muscular dystrophy (FSHD), and uses thereof.  
WO/2013/150153A1
Ketone bodies and ketone body esters maintain or improve muscle power output upon oral administration. Certain esters of hydroxybutyrate monomers are organoleptically acceptable and have high levels of uptake from the gut to the blood th...  
WO/2013/147072A1
The present invention is a cocrystal of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one and a C14-17 fatty acid.  
WO/2013/140787A1
The present invention addresses the problem of providing a novel preventive or therapeutic agent to prevent/treat idiopathic inflammatory myopathy effectively and safely. An antibody or an antibody fragment which specifically binds to DN...  
WO/2013/141202A1
Provided are a method for treating muscle atrophy, and a method and means for promoting muscle hypertrophy. The present invention provides a muscle-building agent characterized by comprising a TRPV1 agonist as an active component; as wel...  
WO/2013/137832A1
The invention relates to myostatin inhibitors, and in particular, to myostatin inhibitors comprising small molecules, and pharmaceutical compositions comprising the myostatin inhibitors. The invention also relates to methods for treating...  
WO/2013/135928A1
The present invention relates to the use of obestatin, or to the nucleotide sequence that codes for same, as an in vitro myogenic agent, and for the production of a drug for muscle regeneration, preferably for musculoskeletal regeneratio...  
WO/2013/138662A1
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNLl polypeptide...  
WO/2013/134660A1
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds ...  
WO/2013/133325A1
[Problem] To provide a compound which has excellent serotonin 5-HT2C receptor activating activity. [Solution] A compound represented by formula (1) or a salt thereof. (In the formula, ring A represents an optionally substituted aromatic ...  
WO/2013/129443A1
Provided are: a novel compound having an excellent Aurora-A-selective inhibitory activity and useful as an anti-cancer agent that can be administered orally; a novel anti-tumor effect enhancer for a microtube agonist comprising a taxane-...  
WO/2013/129603A1
The present invention addresses the problem of developing and providing a method for designating a disease that relates to the amount of TDP-43 existing in cells and a method for producing a TDP-43 binding inhibitor. By collecting cells ...  
WO/2013/125674A1
[Problem] A main objective of the present invention is to provide a cell preparation useful for treatment of diseases in bone joints and repairing muscles which have been degenerated or damaged. [Solution] The present invention provides ...  
WO/2013/125634A1
 Provided are a TLR4 agent, a tissue homeostasis agent, a hepatocyte growth factor inducer, a tissue repairing agent, and a sirtuin inducer using hyaluronic acid fragments. Hyaluronic acid fragments selected from sizes of 2-20 sugar ...  
WO/2013/126919A1
Novel fusion proteins compromising nuclear factor kB essential modulator- binding (NEMO) domain or a fragment thereof and MCoTI-I/II or a fragment thereof, and their use for the treatment of inflammatory diseases and other medical condit...  
WO/2013/126521A1
Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and/or sexual dysfunction in an individual via the use of stably expr...  
WO/2013/122029A1
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...  
WO/2013/122188A1
Provided is an agent, said agent having an improved effect of enhancing NO production, for preventing or ameliorating vascular endothelial malfunction and symptoms that occur with the progress of vascular endothelial malfunction such as ...  
WO/2013/118773A1
The purpose of the present invention is to provide a prophylactic or therapeutic agent for idiopathic inflammatory myopathies and idiopathic inflammatory myopathies in which steroid myopathy is induced during the treatment thereof. The p...  
WO/2013/118854A1
Provided is a drug for the treatment and/or prevention of pain or a drug for the treatment and/or prevention of sodium channel-mediated diseases. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: Ar...  
WO/2013/114413A1
The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl- [ 6- ( 4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl ) - naphthalen-2-yl-methyl ] -ammonium chloride or other pharmaceutical...  
WO/2013/113772A1
The invention relates to a medicament containing cimicifuga, extracts from cimicifuga, saponine-containing fractions of cimicifuga for use with muscle weakness and for prevention of muscle weakness, in particular sarcopenia and myocardia...  
WO/2013/113857A1
The invention relates to a pharmaceutical dosage form comprising (1r,4r)-6'-Fluoro-(N- methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane -1,1'-pyrano[3,4,b]- indol]-4-amine or a physiologically acceptable salt there...  
WO/2013/116691A1
The present invention relates to methods for improving muscle strength and treating muscular dystrophy.  
WO/2013/112053A1
The current invention provides animproved oligonucleotide and its use for treating, ameliorating, preventing and/or delaying DMD or BMD.  
WO/2013/108926A1
The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis, which contains an anacardic acid derivative, and a method of screening for a prophylactic and/or therapeutic drug for amyotrophic l...  
WO/2013/102904A1
Disclosed herein are AAV-based viral vectors encoding GNE from muscle-specific and non- muscle specific promoters, and the use of same in treating myopathies associated with altered GNE function.  
WO/2013/102265A1
Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTa...  
WO/2013/100190A1
The purpose of the invention is to provide a drug to produce highly efficient skipping of exons 55, 45, 50, and 44 of a human dystrophin gene. The invention provides an oligomer that makes it possible to skip exons 55, 45, 50, and 44 of ...  
WO/2013/101949A2
The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentratio...  
WO/2013/099982A1
A shikuwasa (Okinawa lime) extract, preferably an extract of a fruit or a leaf of shikuwasa with water and/or an organic solvent, a supercritical extract of a fruit or a leaf of shikuwasa or a subcritical extract of a fruit or a leaf of ...  
WO/2013/100566A1
A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a compo...  
WO/2013/100566A8
A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a compo...  

Matches 101 - 150 out of 15,685